Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adverse reaction monitoring study of cefazolin sodium pentahydrate for injection
ChiCTR1900023508Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefazolin, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Adverse reaction. Started Nov 2017; status: recruiting.
02
Drugs
cefazolin
Beyond the preview
Go deeper on ChiCTR1900023508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023508.